AI Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is a widespread liver condition linked to metabolic syndrome and is a leading cause of liver-related health issues, including cirrhosis and the need for transplants.
- Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD, and while non-invasive diagnostic tools are emerging, liver biopsy remains the primary method for confirming NASH.
- Despite ongoing research and clinical trials, there are currently no approved treatments for NAFLD, highlighting a significant gap in knowledge and management at the community level that this expert review seeks to address.
Article Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. In spite of promising performance of non-invasive tools, liver biopsy remains the gold standard test for NASH diagnosis. Over decades, many drugs have been investigated in phase 2 and 3; however, no approved therapy to date. Despite the alarming global rates of NAFLD, there are no local community-based studies on the prevalence of NAFLD or local practice guidelines on its management; this expert review aims to fill this gap.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778754 | PMC |
| http://dx.doi.org/10.15537/smj.2019.6.23980 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!